HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

6th Edition of World Congress on Infectious Diseases

June 24-26, 2024 | Paris, France

June 24 -26, 2024 | Paris, France
Infection 2023

Pietro Salvatori

Speaker at Infectious Diseases Conference - Pietro Salvatori
Private Practice, Italy
Title : Efficacy and safety of inhalation of nebulized ethanol in covid-19 treatment. A randomized clinical trial


Background: This study was designed to evaluate the efficacy and safety of nebulized ethanol (EtOH) in the treatment of COVID-19.

Methods: A RCT of 99 symptomatic and RT-PCR-positive patients admitted to a hospital receiving Remdesevir-Dexamethasone was conducted. They were randomly assigned to receive distilled water spray (control group, CG) or 35% EtOH spray (intervention group, IG). Both groups inhaled three puffs of spray (nebulizer) every 6 h for a week. Primary outcome: Global Symptomatic Score (GSS) between the two groups at the first visit and on days 3, 7, and 14. Secondary outcomes: Clinical Status Scale (CSS, a 7-point ordinal scale ranging from death to complete recovery) and readmission rate.

Results: Forty-four and 55 patients were enrolled in the intervention and control groups, respectively. Although there was no difference at admission, the GSS and CSS improved significantly in the IG (p=0.016 and p=0.001, respectively). The IG readmission rate was significantly lower (zero vs. 10.9%; p=0.02).

Conclusions: Inhaled-nebulized EtOH is effective in rapidly improving the clinical status and reducing further treatment. Due to its low cost, availability, and absent/tolerable adverse events, further research is recommended on curative and preventive EtOH effects.

Audience take-away:

  • Friendly use in daily practice
  • Ethanol inhalation will greatly reduce costs for human and health provider resources
  • This research can be easily extended in any research center, mostly in low-income countries
  • It provides a practical solution for fast recovery from Covid-19 at negligible toxicity
  • It provides new information to assist in pandemic management
  • Great potential for saving lives and reducing financial burden


Dr. Pietro Salvatori graduated at the University of Florence Medical School, Italy. He earned specialization in General Surgery, Otorhinolaryngology, and Maxillo-Facial Surgery. He was a Research Fellow at the University of Liverpool, served in several Institutions, and ended his hospital career as Head of the ENT-H&N Department of the Humanitas San Pio X Hospital, Milan, Italy. At present, Dr. Salvatori acts as a freelance Head & Neck Surgeon.

Most of both his work and research dealt with head and neck cancer. Dr. Salvatori published more than 50 papers.

During the recent pandemic, he made research with international colleagues and published on ethanol inhalation to treat SARS-CoV-2 infection and Covid-19.